Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia
Authors
Keywords
-
Journal
LEUKEMIA
Volume 27, Issue 8, Pages 1659-1665
Publisher
Springer Nature
Online
2013-02-19
DOI
10.1038/leu.2013.52
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Risk categories and refractory CLL in the era of chemoimmunotherapy
- (2012) T. Zenz et al. BLOOD
- Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence
- (2012) S. Arai et al. BLOOD
- Massive evolution of the immunoglobulin heavy chain locus in children with B precursor acute lymphoblastic leukemia
- (2012) C. Gawad et al. BLOOD
- Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia
- (2012) M. Faham et al. BLOOD
- Minimal Residual Disease Quantification Is an Independent Predictor of Progression-Free and Overall Survival in Chronic Lymphocytic Leukemia: A Multivariate Analysis From the Randomized GCLLSG CLL8 Trial
- (2012) Sebastian Böttcher et al. JOURNAL OF CLINICAL ONCOLOGY
- Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
- (2012) A C Rawstron et al. LEUKEMIA
- Allogeneic stem cell transplantation for chronic lymphocytic leukemia: Lessons to be learned from minimal residual disease studies
- (2011) Sebastian Böttcher et al. BLOOD REVIEWS
- Update on Therapy of Chronic Lymphocytic Leukemia
- (2011) John G. Gribben et al. JOURNAL OF CLINICAL ONCOLOGY
- High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment
- (2011) A. C. Logan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Disease-Specific Methods and Strategies for Monitoring Relapse Following Allogeneic Stem Cell Transplantation. Part II: Chronic Leukemias, Myeloproliferative Neoplasms, and Lymphoid Malignancies
- (2010) Nicolaus Kröger et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial
- (2010) P. Dreger et al. BLOOD
- Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?
- (2010) Abraham M. Varghese et al. Current Hematologic Malignancy Reports
- TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors
- (2009) H. E. Kohrt et al. BLOOD
- Qualitative and quantitative polymerase chain reaction monitoring of minimal residual disease in relapsed chronic lymphocytic leukemia: early assessment can predict long-term outcome after reduced intensity allogeneic transplantation
- (2009) L. Farina et al. HAEMATOLOGICA
- Standardized MRD flow and ASO IGH RQ-PCR for MRD quantification in CLL patients after rituximab-containing immunochemotherapy: a comparative analysis
- (2009) S Böttcher et al. LEUKEMIA
- Measurement and Clinical Monitoring of Human Lymphocyte Clonality by Massively Parallel V-D-J Pyrosequencing
- (2009) S. D. Boyd et al. Science Translational Medicine
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)
- (2008) Carmen D. Schweighofer et al. BRITISH JOURNAL OF HAEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started